The global rare biomarkers specimen collection and stabilization market size was estimated at USD 41,990 million in 2024 and is projected to be worth around USD 1,62,630 million by 2034, growing at a CAGR of 14.5% from 2025 to 2034.
| Industry Worth | Details |
| Market Size in 2025 | USD 48,080 Million |
| Market Size by 2034 | USD 1,62,630 Million |
| Market Growth Rate from 2025 to 2034 | CAGR of 14.5% |
The rare biomarkers specimen collection and stabilization market refers to the collection and preservation of biological samples containing rare or low-abundance molecules that act as indications of specific biological processes, situations, or diseases. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process or a condition, or a disease.
The rising prevalence of chronic conditions leads to the need for early detection. According to a report published in March 2025, the global burden and biomarkers of cardiovascular disease attributable to ambient particulate matter pollution (APMP).
According to a report published in June 2024, cardiovascular diseases among Indian Older Adults are notable. In India, CVDs are the leading cause of death and disability and accounted for 31.8% of all deaths and 14.7% disability adjusted life years (DALYs) globally in the year 2017. In India, key risk factors for CVDs include sedentary lifestyle, diabetes, poor diet, obesity, hypertension (HT), and high cholesterol.
According to a report published on cardiovascular health and disease in China in 2022, the number of current CVD patients in China is estimated to be approximately 330 million, including 245 million hypertension cases, 43.5 million peripheral artery disease cases, 2 million congenital heart disease cases, 2.5 million rheumatic heart disease cases, 13 million stroke cases, and 11.39 million coronary heart disease cases.
Sudhir Hasbe, Chief Product Officer at Neo4i, commented, “We are thrilled to expand our partnership with QIAGEN Digital Insights, which has been at the forefront of using graph technology within life sciences. As we develop new ways to enhance and integrate the QIAGEN biomedical knowledge graph, we are confident that we will unlock new possibilities for biopharma companies, driving innovation and enhancing patient outcomes.”
Aiden Synnott, PhD, Corporate Vice President, Global Discovery Services at Charles River, said, “Being a part of DanubeNeuro and collaborating with CEBINA aligns perfectly with our commitment to advancing scientific research and innovation.” “We are eager to contribute our expertise to this acceleration program and support the next generation of breakthroughs in neuroscience.”
North America
North America dominated the global rare biomarkers specimen collection and stabilization market in 2024. Ongoing innovations in biomarker research are leading to the development of new biomarkers associated with many diseases.
United States:
According to a report published in October 2024 by the Centers for Disease Control and Prevention, heart disease is the main cause of death for men, women, and people of most racial and ethnic groups in the United States.
Asia Pacific
Asia Pacific is anticipated to grow at the fastest rate during the forecast period. Rising research and development activities and advanced technologies are driving the growth of the rare biomarkers specimen collection and stabilization market.
The rare biomarkers specimen collection and stabilization market is highly competitive, with leading pharmaceutical companies like Charles River Laboratories and Thermo Fischer Scientific Inc. holding the highest market share.
The market is dominated by many pharmaceutical companies for their significant contributions to disease diagnosis and treatment. Based on the recent data, the top three companies leading are
The revenue was $4.13 billion, representing a 3.9% increase over the previous year 2023 on a reported basis of Charles River Laboratories.
Thermo Fischer Scientific, Inc., the revenue was $32.22 billion in 2020 and $42.88 billion in 2024 on a reported basis.
Published by Ajit Bansod
